Fig. 1 · Structure

Documents & Downloads

Selamectin

Cat. No. A12363 CAS 220119-17-5
Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Selamectin Research Summary

This section summarizes 4 in vitro studies of Selamectin from 2 published references. In vitro models include M. ulcerans S1013; purified Mycobacterium smegmatis DprE1 recombinant enzyme.

Selamectin In Vitro Studies

In M. ulcerans S1013 cultures, Selamectin required AUC/MIC ratios between 10 and 15 for a bactericidal effect corresponding to 99.99% killing. In M. ulcerans S1012, Selamectin yielded an MIC of 2 μg/mL. Selamectin inhibited purified Mycobacterium smegmatis DprE1 recombinant enzyme with an IC50 of 2.6 ± 1.1 µM. For L282F M. smegmatis DprE1, the Selamectin IC50 was 1.0 ± 0.7 µM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Bactericidal activity in M. ulcerans cultures

Cell-based study · M. ulcerans S1013 [1]

M. ulcerans S1013 cultures were exposed to Selamectin, with colony-forming units measured after incubation. AUC/MIC ratios between 10 and 15 were required to achieve 99.99% killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C.bacterial killing 99.99% killing[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 2, 4, 8, 16 and 32 μg/mL
Exposure duration
0, 3, 7, 14 and 21 days
Method
Cultures were grown at 30°C in the presence of
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: Selamectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > M. ulcerans kill-kinetic assay (S11, S12, S14); Results > Selamectin kills M. ulcerans (S26)

Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C.: Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C. — Materials and Methods > M. ulcerans kill-kinetic assay (S14); Results > Selamectin kills M. ulcerans (S26)

Inhibition of purified mycobacterial enzyme activity

Biochemical assay · purified Mycobacterium smegmatis DprE1 recombinant enzyme [2]

Purified Mycobacterium smegmatis DprE1 recombinant enzyme was incubated with Selamectin in a reaction mixture. Enzyme activity measured using the Amplex Red/peroxidase coupled assay yielded an IC50 of 2.6 ± 1.1 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Enzyme activity was determined with the Amplex Red/peroxidase coupled assayIC50 Wild-type: IC50 = 2.6 ± 1.1 µM[2]

Literature-Reported Treatment Conditions

Method
incubated in a reaction mixture
Reported limits
Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Selamectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. Avermectins Inhibit the DprE1 Enzyme In Vitro (S11, S12); 4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S75, S76, S81); Table 2 (T2.r4); Table 3 (T3.r1)

Enzyme activity was determined with the Amplex Red/peroxidase coupled assay: Enzyme activity was determined with the Amplex Red/peroxidase coupled assay; comparator: enzyme activity in the absence of inhibitors — 2. Results > 2.2. Avermectins Inhibit the DprE1 Enzyme In Vitro (S12); 4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S75); Table 3 (T3.r1)

Growth inhibition in M. ulcerans cultures

Cell-based study · M. ulcerans strains S1012 [1]

M. ulcerans strains S1012 were incubated with Selamectin and assessed using a color-conversion readout. The reported MIC was 2 μg/mL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC90) was used to define MIC values.MIC 2 μg/mL[1]

Literature-Reported Treatment Conditions

Exposure duration
at 30°C for 8 days before addition of 20 μL of a resazurin solution (0.125 mg/mL), followed by overnight incubation at 37°C
Method
incubated in the presence of the drug
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Selamectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Bacterial strains, general growth conditions and reagents (S2); Materials and Methods > Drug susceptibility assays (S5, S8, S10); Table 1 (T1.h1, T1.h2, T1.r1)

The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC90) was used to define MIC values.: The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC90) was used to define MIC values. — Materials and Methods > Drug susceptibility assays (S10); Table 1 (T1.h1, T1.h2, T1.r1)

Enzyme inhibition in a mycobacterial variant

Cell-based study · L282F M. smegmatis DprE1 [2]

L282F M. smegmatis DprE1 was incubated with Selamectin in a reaction mixture. The measured IC50 was 1.0 ± 0.7 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IC50 determination of selamectinIC50 1.0 ± 0.7 µM[2]

Literature-Reported Treatment Conditions

Method
incubated in a reaction mixture
Reported limits
Not stated in the sentences used: dose, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Selamectin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

4. Materials and Methods > 4.5. DprE1 Enzymatic Studies (S76, S81); Figure 4 legend (S110); Table 3 (T3.h1, T3.r5)

IC50 determination of selamectin: IC50 determination of selamectin; comparator: enzyme activity in the absence of inhibitors — Figure 4 legend (S110); Table 3 (T3.h1, T3.r5)

Specifications

Manufacturer Adooq Bioscience
CAS Number 220119-17-5
Formula C43H63NO11
Molecular Weight 769.96
SMILES
C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]\5[C@@]4([C@@H](C=C(/C5=N/O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)\C)O[C@@H]1C7CCCCC7

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (111.69 mM)
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Selamectin Research References

  1. [1] Scherr N, Pluschke G, Thompson CJ, et al. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. PLoS Negl Trop Dis (2015). PMID: 26270480 DOI: 10.1371/journal.pntd.0003996 Source material
  2. [2] Ezquerra-Aznárez JM, Degiacomi G, Gašparovič H, et al. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. Int J Mol Sci (2022). PMID: 35054958 DOI: 10.3390/ijms23020771 Source material

Added to your cart

View Cart Checkout
Loading...